Cargando…

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

BACKGROUND: On July 30, 2021, the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) was approved in Israel for persons who were 60 years of age or older and who had received a second dose of vaccine at least 5 months earlier. Data are needed regarding t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bar-On, Yinon M., Goldberg, Yair, Mandel, Micha, Bodenheimer, Omri, Freedman, Laurence, Kalkstein, Nir, Mizrahi, Barak, Alroy-Preis, Sharon, Ash, Nachman, Milo, Ron, Huppert, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461568/
https://www.ncbi.nlm.nih.gov/pubmed/34525275
http://dx.doi.org/10.1056/NEJMoa2114255
_version_ 1784572013883424768
author Bar-On, Yinon M.
Goldberg, Yair
Mandel, Micha
Bodenheimer, Omri
Freedman, Laurence
Kalkstein, Nir
Mizrahi, Barak
Alroy-Preis, Sharon
Ash, Nachman
Milo, Ron
Huppert, Amit
author_facet Bar-On, Yinon M.
Goldberg, Yair
Mandel, Micha
Bodenheimer, Omri
Freedman, Laurence
Kalkstein, Nir
Mizrahi, Barak
Alroy-Preis, Sharon
Ash, Nachman
Milo, Ron
Huppert, Amit
author_sort Bar-On, Yinon M.
collection PubMed
description BACKGROUND: On July 30, 2021, the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) was approved in Israel for persons who were 60 years of age or older and who had received a second dose of vaccine at least 5 months earlier. Data are needed regarding the effect of the booster dose on the rate of confirmed coronavirus 2019 disease (Covid-19) and the rate of severe illness. METHODS: We extracted data for the period from July 30 through August 31, 2021, from the Israeli Ministry of Health database regarding 1,137,804 persons who were 60 years of age or older and had been fully vaccinated (i.e., had received two doses of BNT162b2) at least 5 months earlier. In the primary analysis, we compared the rate of confirmed Covid-19 and the rate of severe illness between those who had received a booster injection at least 12 days earlier (booster group) and those who had not received a booster injection (nonbooster group). In a secondary analysis, we evaluated the rate of infection 4 to 6 days after the booster dose as compared with the rate at least 12 days after the booster. In all the analyses, we used Poisson regression after adjusting for possible confounding factors. RESULTS: At least 12 days after the booster dose, the rate of confirmed infection was lower in the booster group than in the nonbooster group by a factor of 11.3 (95% confidence interval [CI], 10.4 to 12.3); the rate of severe illness was lower by a factor of 19.5 (95% CI, 12.9 to 29.5). In a secondary analysis, the rate of confirmed infection at least 12 days after vaccination was lower than the rate after 4 to 6 days by a factor of 5.4 (95% CI, 4.8 to 6.1). CONCLUSIONS: In this study involving participants who were 60 years of age or older and had received two doses of the BNT162b2 vaccine at least 5 months earlier, we found that the rates of confirmed Covid-19 and severe illness were substantially lower among those who received a booster (third) dose of the BNT162b2 vaccine.
format Online
Article
Text
id pubmed-8461568
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Massachusetts Medical Society
record_format MEDLINE/PubMed
spelling pubmed-84615682021-09-27 Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel Bar-On, Yinon M. Goldberg, Yair Mandel, Micha Bodenheimer, Omri Freedman, Laurence Kalkstein, Nir Mizrahi, Barak Alroy-Preis, Sharon Ash, Nachman Milo, Ron Huppert, Amit N Engl J Med Original Article BACKGROUND: On July 30, 2021, the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) was approved in Israel for persons who were 60 years of age or older and who had received a second dose of vaccine at least 5 months earlier. Data are needed regarding the effect of the booster dose on the rate of confirmed coronavirus 2019 disease (Covid-19) and the rate of severe illness. METHODS: We extracted data for the period from July 30 through August 31, 2021, from the Israeli Ministry of Health database regarding 1,137,804 persons who were 60 years of age or older and had been fully vaccinated (i.e., had received two doses of BNT162b2) at least 5 months earlier. In the primary analysis, we compared the rate of confirmed Covid-19 and the rate of severe illness between those who had received a booster injection at least 12 days earlier (booster group) and those who had not received a booster injection (nonbooster group). In a secondary analysis, we evaluated the rate of infection 4 to 6 days after the booster dose as compared with the rate at least 12 days after the booster. In all the analyses, we used Poisson regression after adjusting for possible confounding factors. RESULTS: At least 12 days after the booster dose, the rate of confirmed infection was lower in the booster group than in the nonbooster group by a factor of 11.3 (95% confidence interval [CI], 10.4 to 12.3); the rate of severe illness was lower by a factor of 19.5 (95% CI, 12.9 to 29.5). In a secondary analysis, the rate of confirmed infection at least 12 days after vaccination was lower than the rate after 4 to 6 days by a factor of 5.4 (95% CI, 4.8 to 6.1). CONCLUSIONS: In this study involving participants who were 60 years of age or older and had received two doses of the BNT162b2 vaccine at least 5 months earlier, we found that the rates of confirmed Covid-19 and severe illness were substantially lower among those who received a booster (third) dose of the BNT162b2 vaccine. Massachusetts Medical Society 2021-09-15 /pmc/articles/PMC8461568/ /pubmed/34525275 http://dx.doi.org/10.1056/NEJMoa2114255 Text en Copyright © 2021 Massachusetts Medical Society. All rights reserved. This article is made available via the PMC Open Access Subset for unrestricted re-use, except commercial resale, and analyses in any form or by any means with acknowledgment of the original source. PMC is granted a license to make this article available via PMC and Europe PMC, subject to existing copyright protections.
spellingShingle Original Article
Bar-On, Yinon M.
Goldberg, Yair
Mandel, Micha
Bodenheimer, Omri
Freedman, Laurence
Kalkstein, Nir
Mizrahi, Barak
Alroy-Preis, Sharon
Ash, Nachman
Milo, Ron
Huppert, Amit
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
title Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
title_full Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
title_fullStr Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
title_full_unstemmed Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
title_short Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
title_sort protection of bnt162b2 vaccine booster against covid-19 in israel
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461568/
https://www.ncbi.nlm.nih.gov/pubmed/34525275
http://dx.doi.org/10.1056/NEJMoa2114255
work_keys_str_mv AT baronyinonm protectionofbnt162b2vaccineboosteragainstcovid19inisrael
AT goldbergyair protectionofbnt162b2vaccineboosteragainstcovid19inisrael
AT mandelmicha protectionofbnt162b2vaccineboosteragainstcovid19inisrael
AT bodenheimeromri protectionofbnt162b2vaccineboosteragainstcovid19inisrael
AT freedmanlaurence protectionofbnt162b2vaccineboosteragainstcovid19inisrael
AT kalksteinnir protectionofbnt162b2vaccineboosteragainstcovid19inisrael
AT mizrahibarak protectionofbnt162b2vaccineboosteragainstcovid19inisrael
AT alroypreissharon protectionofbnt162b2vaccineboosteragainstcovid19inisrael
AT ashnachman protectionofbnt162b2vaccineboosteragainstcovid19inisrael
AT miloron protectionofbnt162b2vaccineboosteragainstcovid19inisrael
AT huppertamit protectionofbnt162b2vaccineboosteragainstcovid19inisrael